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Objective: To estimate the unit costs of administering intravenous (IV) biological agents in 
day hospitals (DHs) in the Spanish National Health System.
Patients and methods: Data were obtained from 188 patients with rheumatoid arthritis, 
collected from nine DHs, receiving one of the following IV therapies: infliximab (n=48), 
rituximab (n=38), abatacept (n=41), or tocilizumab (n=61). The fieldwork was carried out 
between March 2013 and March 2014. The following three groups of costs were considered: 
1) structural costs, 2) material costs, and 3) staff costs. Staff costs were considered a fixed cost 
and were estimated according to the DH theoretical level of activity, which includes, as well as 
personal care of each patient, the DH general activities (complete imputation method, CIM). In 
addition, an alternative calculation was performed, in which the staff costs were considered a 
variable cost imputed according to the time spent on direct care (partial imputation method, PIM). 
All costs were expressed in euros for the reference year 2014.
Results: The average total cost was €146.12 per infusion (standard deviation [SD] ±87.11; 
CIM) and €29.70 per infusion (SD ±11.42; PIM). The structure-related costs per infusion varied 
between €2.23 and €62.35 per patient and DH; the cost of consumables oscillated between €3.48 
and €20.34 per patient and DH. In terms of the care process, the average difference between 
the shortest and the longest time taken by different hospitals to administer an IV biological 
therapy was 113 minutes.
Conclusion: The average total cost of infusion was less than that normally used in models 
of economic evaluation coming from secondary sources. This cost is even less when the staff 
costs are imputed according to the PIM. A high degree of variability was observed between 
different DHs in the cost of the consumables, in the structure-related costs, and in those of the 
care process.
Keywords: day hospitals, rheumatoid arthritis, intravenous biological agents, unit cost of 
infusion, variability, care process
Introduction
In recent years, there has been an important change in the care of patients whose chronic 
or prolonged processes require intravenous (IV) therapies. This change is occurring 
because of the appearance of biological therapies, which in some cases cannot be 
administered in the patient’s home.
“Day hospitalization” has become the best way to administer IV therapies, 
without the need for admission and with the same quality of care as that of an 
admitted patient, but with fewer risks and associated costs.1 That is why activity in 
day hospital (DH) in Spain has been increasing in recent years, with 4 million2 
patients being cared for in this way in 2012. This increase in the level of health 
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introduce mechanisms for controlling expenditure in DH. 
So in 2009, the Spanish Ministry of Health and Social 
Policy issued a Guide to Standards and Recommendations 
for the running of DH in Spain.3 Likewise, scientific 
societies began to develop standards of management and 
quality indicators for different specializations4 showing 
theoretical recommendations for the operation of a DH. 
However, no information is available about the costs of 
a DH related to the care process, the resources which it 
consumes, or about the possible effect that the manage-
ment of the DH has on the cost of the therapies admin-
istered. In fact, differences in the clinical management 
of patients in DH may have a very strong impact on the 
costs of IV therapies and specifically on their adminis-
tration – differences between centers can reach €7,000 
per patient per year5 according to data obtained from a 
study carried out in France on patients with rheumatoid 
arthritis (RA).
Recently published studies reveal that the most common 
problems observed in Spanish DH, from the management 
point of view, are a saturation of patients in relation to the 
number of available beds/chairs and the delay in receiving 
medication from the hospital pharmacy.1 Another notable 
problem is that of the existing variability between different 
DHs in Spain.6,7 The conclusion of a very recent study is 
that none of the rheumatology DHs would currently reach 
excellence,8 which points to the need to study more deeply 
their care processes in order to improve their efficiency, and 
thence to reevaluate the costs of the therapies administered, 
including the IV ones. The result of the lack of research into 
this subject is that in most of the related works published in 
Spain, the costs of administering IV therapies in DH come 
from local health service tariffs and other secondary data. 
Consequently, the main aim of this work is to estimate the 
unit costs of administering IV drugs in DH in the Spanish 
National Health System, using primary data and taking 
into account the resources consumed in providing the care 
process in a DH.
Patients and methods
As this study was classified as an EPA-OD by the Span-
ish Agency of Medicines and Sanitary Products and was 
approved by the University Hospital of Getafe Ethics Com-
mittee written informed consent was not required. A total 
of 188 patients were recruited in nine DHs belonging to the 
Spanish National Health System. The fieldwork was carried 
out between March 2013 and March 2014. The patients 
diagnosed with RA,9 aged 18 years or older, and undergoing 
therapy with one of the following IV biological agents were 
included: infliximab, rituximab, abatacept, or tocilizumab. 
The distribution of patients between IV therapies was: 
infliximab (n=48), rituximab (n=38), abatacept (n=41), or 
tocilizumab (n=61). Rhythm of drug administration was not 
considered, but each visit was considered as independent 
IV infusion.
The DHs included in the sample were selected on the 
basis of their typology; all of them were polyvalent. This 
study preserved the anonymity of the hospitals included 
in the sample, and the nomenclature used to present the 
results was completely random with no relation between the 
numbering (DH1, DH2, etc). The complete list of hospitals 
was as follows: Hospital Universitari de Bellvitge, Hospital 
Universitario de Getafe, Hospital Universitario Fundación 
Jiménez Díaz, Hospital Universitario Miguel Servet, Hospital 
de la Santa Creu i Sant Pau, Hospital Universitario Marqués 
de Valdecilla, Hospital Universitario Virgen del Rocío, 
Hospital General Universitario de Valencia, and Hospital 
Virgen de la Salud.
In order to estimate the unit cost of each infusion, person-
nel trained specifically for this study measured the time taken 
by the medical staff in caring for patients during the adminis-
tration of biological agents in all selected DHs. The following 
information about the hospitals was also collected:
•	 Annual structural costs attributed by cost accounting to 
the DH.
•	 Annual costs of maintenance contracts, electromedical 
equipment, information technology, and so on.
•	 Cost of consumable products and medical and nonmedical 
articles, both storable and non-storable, for the pursuit of 
the DH activity.
•	 Number of patients treated in the DH, classified by diag-
nosis and treatment.
•	 Details of the consumables and/or medical articles needed 
to carry out each therapy included in this study.
•	 Standard cost of the DH staff by category and level of 
remuneration, indicating the number of people and the 
annual cost of each category.
•	 Cost of the extraordinary activity of the DH staff and the 
number of patients treated during that activity.
In order to obtain the total unit cost of administering 
IV drugs, three types of costs were taken into account: 
1) costs related to the structure (calculated on the basis of 
the area of the DH in square meter), 2) costs of consum-
able medical and nonmedical materials (obtained from 
the DH accounting records), and 3) staff costs (including 
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an estimate of the cost of administering intravenous biological agents
assistant, a hospital attendant, and an administrative 
employee).
From the methodological point of view, this work is 
governed by the principles of cost accounting, the purpose 
of which is to analyze costs by product or by department. 
The chosen model for the calculation of costs was the so-
called “Full costs” model,10,11 which takes into account 
both the direct costs (directly related to the consumption of 
resources necessary for the provision of medical care) and 
the indirect costs (costs of structure, central departments, etc) 
of the hospitals.
The methods of attributing different types of costs were 
the following (Figure 1):
•	 Structure-related costs: for the estimation of the indirect 
costs of each DH, and subsequently of each IV therapy, 
the cost accounting criteria of the INSALUD’s GECLIF 
system were used, the main aim of which being to stan-
dardize hospitals’ clinical and financial information and 
calculate the cost per process so as to obtain the costs for 
each care activity.3,12 Specifically, the area of each DH 
in square meter was used whenever information about 
the structure-related cost attributable to each group of 
patients was not available in that hospital accounting 
system. Subsequently, from the total activity of each DH, 
a calculation was performed to find the percentage to be 
used to divide these indirect costs between the patients 
who received one of the IV therapies under study.
•	 Costs of consumable materials: as the consumption of 
resources was very similar among all patients, the cost per 
patient was calculated by dividing the cost of the annual 
consumption of medical and nonmedical materials by the 
number of patients cared for in the DH.
•	 Staff costs: the staff of a DH has been grouped into three 
sections: area specialist doctor, nursing, and others. The 
doctor performs a monitoring visit, so his/her function 
is to verify that the patient feels fine and make some 
general questions. For this reason, only three hospitals 
were recorded costs of specialist doctor. In the group of 
“others”, costs of administrative staff, guards, and so on 
have been included. In the base case, it was considered that 
the staff cost is a fixed cost, so the established method of 
calculation (complete imputation method, CIM) imputed 
both the time spent on the direct care of each patient and 
the time that the medical staff devotes to general activities 
within the DH. In other words, this method imputes the 
entire cost of the staff attached to the DH to the patients 
under their care, given that those staffs are needed for 
the medical care provided. This method of assigning 
Figure 1 Methods used to distribute the costs.
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costs thus divides the whole of the DH costs among the 
population under its care, and it is probably the same as 
the method used by the hospitals themselves in their cost 
control. Nevertheless, an alternative calculation has been 
devised (partial imputation method, PIM), which imputes, 
as a cost of the infusion, the cost of the time effectively 
devoted to that particular patient on various tasks that are 
necessary for that infusion. The cost of specialist doctor 
matches in both methods, because their main task is not 
allocated to the DH and we only consider the time spent 
in doing the monitoring visit to the patient.
On the basis of the methods used, the final result of the 
work produced an average total cost per infusion and an 
average cost per minute of infusion, expressed in euros for 
the reference year 2014. The second one was calculated 
in order to eliminate the factor of the time taken for the 
infusion in the treatment of patients with RA, thus facili-
tating the extrapolation of the results of this work to other 
therapies in DH.
In terms of the health care process, the following phases 
in the care of a patient were defined:
•	 Premedication phase: the time spent on activities prior 
to the treatment, related to the administration of drugs 
such as paracetamol, methylprednisolone, and so on. This 
phase applies to the case of rituximab and infliximab.
•	 Infusion or treatment phase: the time between the inser-
tion of the catheter and its removal.
•	 Waiting phase: the time during which the patient remains 
in the room without receiving any medical care, for 
example, the time spent waiting for the nurse to be free 
or the time spent waiting for the medicine to arrive from 
the hospital pharmacy.
Results
The results of the study show that the average total cost of 
administering IV biological agents is €146.12 per infusion 
(CIM). When the PIM is used, the cost is 4.92 times less 
(a total unit cost of €29.70 per infusion; Tables 1 and 2). The 
category of medical staff that devotes the most time to the 
care of patients in the administration of their IV treatments 
is the nursing staff (Table 3).
With regard to the percentage share of each type of cost, 
the results show that the staff costs constitute the greatest 
burden with 83.9% of the unit cost of each infusion, fol-
lowed by the structure-related costs (9.6%) and the cost of 
consumable materials (6.5%, CIM). From the perspective 
of the weightage of each group of costs, a big change in the 
composition of the total cost is observed when using the PIM, 
in which the group of costs with the greatest weightage is that 
of the structure-related costs (47.2%), followed by the costs 
of consumable materials (31.8%) and staff costs (21%, on the 
basis of time spent on direct care; Figures 2 and 3).
The average total cost per minute is €0.89, and the average 
cost of 30 minutes of treatment is €26.74 (CIM); the values 
obtained from the PIM being €0.20 per infusion per minute 
and €5.95 per infusion per half an hour.
With regard to the health care process, the results show 
that the total time spent on caring for patients is divided 
Table 1 average costs per infusion by type of cost and treatment (€) (CiM)
TRT Cost of  
structure
Cost of  
consumables
Staff costs TRT cost  
per minute
TRT cost per 
30 minutesASD Nurse NRSNG ASST Other Total
Infliximab 12.56 9.46 0.14 67.72 41.33 2.13 133.34 0.88 26.32
Rituximab 27.95 9.46 0.71 144.05 87.91 2.13 272.21 0.84 25.26
abatacept 6.25 9.46 0.21 36.97 22.56 2.13 77.58 0.93 28.05
Tocilizumab 9.26 9.46 0.71 49.56 30.24 2.13 101.36 0.91 27.34
average cost 14.01 9.46 0.44 74.57 45.51 2.13 146.12 0.89 26.74
Abbreviations: TRT, treatment; asD, area specialist doctor; nRsng assT, nursing assistant; CiM, complete imputation method (theoretical capacity).
Table 2 average costs per infusion by type of cost and treatment (€) (PiM)
TRT Cost of  
structure
Cost of  
consumables
Staff costs Total TRT cost  
per minute
TRT cost per 
30 minutesASD Nurse NRSNG ASST Other
Infliximab 12.56 9.46 0.14 4.40 0.26 0.00 26.82 0.18 5.29
Rituximab 27.95 9.46 0.71 7.95 0.37 0.00 46.44 0.14 4.31
abatacept 6.25 9.46 0.21 4.90 0.08 0.00 20.89 0.25 7.55
Tocilizumab 9.26 9.46 0.71 4.86 0.37 0.00 24.66 0.22 6.65
average cost 14.01 9.46 0.44 5.53 0.27 0.00 29.70 0.20 5.95
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an estimate of the cost of administering intravenous biological agents
as follows: the treatment phase occupies 64% of the total 
caring time, followed by the waiting phase (28%), and the 
premedication phase, which occupies 8% of the total time 
(Table 4). Large differences were noticed in the lengths of 
the waiting phases at different DHs (Table 5). The shortest 
waiting period was in a hospital where it was 15 minutes, 
contrasting with the hospital with the longest waiting period 
of 68.8 minutes. This waiting period has now reached more 
than one-third (37%) of the total time spent by patients in a 
hospital for the purpose of receiving IV therapies, indicating 
a potential area for improvement with a probable impact both 
on the cost of the DH and, without doubt, on the patients 
themselves.
With regard to variability, big differences were detected 
between DH in Spain, both in terms of structure (depending 
on the type of hospital, mono-specialized vs poly-specialized, 
size, etc) and in terms of the costs of the materials, number 
of staffs employed, hours of operation, number of chairs, 
and process of health care. Some hospitals do not use 
nursing assistants to look after patients, while others 
use seven employed professionals in this category; the 
average is two nursing assistants. With regard to the total 
time devoted to care, differences of up to 113 minutes per 
patient were observed (Figure 4). As for the number of 
chairs, the minimum number observed was four, and the 
maximum was 37.
All these factors affect the costs of IV therapy and 
complicate any comparison between centers, so their dif-
ferent combinations mean that there are differences between 
the DH analyzed (Table 6). If, in addition to the aforemen-
tioned variability, we include in the analysis the criterion of 
imputation of the staff cost, the differences observed, both 
interhospital and intrahospital, are very considerable, and the 
total cost of the infusion can be as much as 90%.
Discussion
The fieldwork for this project was carried out with patients 
diagnosed with RA, which invites one to take other consid-
erations into account before proceeding to extrapolate the 
results obtained for all IV therapies. First of all, it is very 
important to know the distribution of patients for each disease 
group, in order to compare the relative experience in RA 
(Table 7). Then, and as we have indicated in this article, each 
medication requires a certain period of treatment and the use 
of specific medical and nonmedical materials, which defi-
nitely produces variations in the total cost. In order to offer 
homogenous information, the cost per minute of treatment 
was calculated. To a certain extent, this helps to compensate 
for the differences in the duration of the treatment, so that the 
results can be compared with those of other studies.
The average total cost of IV infusion for a patient with RA 
is €146 per infusion, according to the CIM. This cost would be 
Table 3 average times by type of medical staff and treatment (in minutes)
TRT Average  
time of the TRT
Average  
time of the ASD
Average  
time of nursing
Average time  
of the nursing 
assistant
Infliximab 152 0.22 9.88 0.94
Rituximab 323 1.09 17.85 1.35
abatacept 83 0.32 11.00 0.27
Tocilizumab 111 1.08 10.92 1.34
average total 167 0.68 12.41 3.9
Abbreviations: TRT, treatment; asD, area specialist doctor.
Figure 2 average costs per infusion by type of cost (in euros).
Note: Complete imputation method.
Figure 3 average costs per infusion by type of cost (in euros).
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80% lesser if the only criterion for the imputation of the costs 
of the medical staff were the time spent on direct care of the 
patient, obtained by the PIM. The average costs per minute 
would then be €0.20 (PIM) and €0.89 (CIM), and the average 
costs of infusion would be €12 per hour and €53.48 per hour, 
respectively. The main conclusion that we reach is that the 
average cost of infusion determined by this study is less than 
that which is normally used in models for economic evalua-
tion, obtained from the e-Salud database (Table 8).
It is important to point out some key aspects when it 
comes to interpreting our results. Throughout this study, 
we observed a high degree of variability among the DHs 
in Spain. This leads to a greater deviation in the average. 
Specifically, there is a high variability both in the cost of the 
consumables used in each DH and in the structure-related 
costs. The latter, when assigned to infusion in different 
hospitals, vary between €2.23 and €62.35 per patient and 
DH, the average structure-related cost for infusion being 
€14.01. As for the average cost of consumables, it oscillates 
between €3.48 and €20.34 per patient and DH, the average 
cost of consumables for infusion being €9.46. In the case of 
the structure-related costs, the characteristics of the hospital 
building itself, which in some cases, whether because of 
its size (a larger or smaller area in square meter), location 
(a high-rise building or a single floor, in the same building as 
the hospitalization or surgical area), air-conditioning systems, 
equipment used, and so on, can justify the differences occur-
ring between these costs, regardless of the DH own activity. 
In the case of the consumables, although the standards for the 
application of procedures are more or less well established in 
hospital centers, there are some relevant differences. In this 
study, we did not analyze differences between protocols used 
to drug administration, because we used real data collected in 
each hospital. But it would be desirable to carry out a study 
in greater depth, in order to compare adherence to the same 
or different protocols at each hospital, which would reveal 
more information about the reasons why their consumption 
is higher in one hospital than in another, based on the cost 
data supplied by the centers.
In some of our neighboring countries, studies have been 
carried out to calculate the cost per infusion of biological 
treatments for patients with RA, based on the time taken to 
administer those treatments. In particular, Soini et al13 cal-
culated the cost per infusion of biological agents for RA in 
Finland, using the public tariffs of Finnish hospitals. These 
authors obtained average costs for the administration of inf-
liximab, rituximab, abatacept, and tocilizumab of €275.34, 
€434.16, €258.39, and €227.41, respectively.13,14 These data 
are in line with those of our study and reinforce the idea that 
when using secondary sources the resulting costs of infusion 
are higher than those obtained when primary sources are 
used. In this way, the study of Soini et al13 shows a cost that 
trebles the cost shown in our data in the case of abatacept. 
In contrast, in the analysis carried out by Wong et al,15 we 
observed an average cost for the administration of biologi-
cal treatments of US$226 (2008), equivalent to €157.3514 
(2014). This figure is very close to the one obtained in our 
own study (€146.12).
Yazici et al16 showed the duration of biological therapy 
in patients with RA in the US. This study estimates infusion 
times of 130, 216, and 409 minutes per patient for abatacept, 
infliximab, and rituximab, respectively. These data are in line 
with the results of our study, with regard to the “ranking” of 
times per treatment, but they are a little higher with regard 
to the total time for each treatment. These differences 
could well be related to possible differences between the 
health care processes in the Spanish and US health systems. 
Of particular interest is the waiting time recorded in the 
American study, in which the average for the three treat-
ments analyzed is 17.8 minutes. Our results fix the length 
of the waiting phase at an average of 47 minutes. Although 
Table 4 average times by patient phases and treatment (in minutes)








Infliximab 152 1 106 45
Rituximab 323 57 213 53
abatacept 83 0 37 46
Tocilizumab 111 0 66 45
average total 167 14 106 47
Abbreviation: TRT, treatment.
Table 5 Weight (%) of the waiting phase out of the total time, 
by day hospital




% of TT Improvement  
required to equal the 
most efficient (min)
Dh1 164 56.9 35 41.3
Dh2 145 44.0 30 28.4
Dh3 138 31.6 23 16.0
Dh4 110 40.4 36 24.8
Dh5 364 66.8 18 51.2
Dh6 164 30.7 19 15.1
Dh7 188 68.8 37 53.2
Dh8 107 15.6 15 0.0
Dh9 184 68.2 37 52.6
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an estimate of the cost of administering intravenous biological agents
Figure 4 Ranking of hospitals, calculated in parts per unit, by average cost per type of resource (complete imputation method).
Abbreviations: TRT, treatment; Dh, day hospital; CsTs, costs; asst, assistant.
Table 6 Costs by criterion of imputation of staff costs and day hospital (€)
DH Complete imputation method Partial imputation method Variation from 
total cost (%)Average 
total cost
Cost/min Cost/30 min Average 
cost total
Cost/min Cost/30 min
Dh1 165.59 0.93 28.04 77.15 0.45 13.59 −53
Dh2 71.51 0.47 14.23 22.01 0.15 4.51 −69
Dh3 75.44 0.52 15.45 19.21 0.14 4.25 −75
Dh4 139.79 1.03 30.92 34.76 0.29 8.67 −75
Dh5 150.93 0.85 25.36 34.16 0.22 6.54 −77
Dh6 99.14 0.65 19.37 9.77 0.08 2.32 −90
Dh7 211.52 1.07 32.06 32.96 0.19 5.69 −84
Dh8 84.32 0.78 23.34 14.41 0.13 3.99 −83
Dh9 176.36 0.72 21.63 26.79 0.13 3.88 −85
Abbreviations: Dh, day hospital; min, minutes.
these differences are very probably related, at least in part, 
to the count of activities included under this section in both 
studies, they invite one to consider whether improvements 
could be introduced into the health care process in Spain. As 
already suggested by Román-Ivorra et al,1 we may be able 
to reduce the time spent on the preparation of the drugs by 
making improvements in the health care process. It is worth 
noting that, from the point of view of efficiency, the ideal 
would be that, in cases in which, in this phase, the patient 
is occupying an infusion post needed by another patient 
because no other posts are available (thus involving a certain 
opportunity cost); this additional time component (the wait-
ing phase) should be as short as possible, so that both the 
patient and the medical center can devote to the treatment the 
time that is strictly necessary, avoiding idle time or waiting 
time during reception, positioning, caring, treatment, and 
release from the center. It seems reasonable to think that, 
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Table 8 Unit costs of intravenous infusions of 2 hours
Description Year Original  
cost €
Cost updated 
to € of 2014
nursing: perfusion of drugs between 0.5 and 2 hours 2003 122.51 154.54
nursing: perfusion of drugs for 2 hours 2003 200.47 252.88
nursing: perfusion of drugs for 0.5 hour 2003 100.24 126.45
Note: Data obtained from spanish health Costs Database: esalud [internet]. Barcelona: Oblikue Consulting, s.l. 2007 [date of access 30/11/16]. available from: http://www.
oblikue.com/bddcostes/.17
waiting period could be an indicator of the degree of effi-
ciency of the center’s DH, in those cases in which the patient 
is occupying a resource, such as an infusion chair, which is 
needed to treat a new patient who then has to wait until it 
is available, and which depends directly on the organiza-
tion and the resources of each center. The estimate of the 
waiting time does not include aspects such as early arrival 
since we have defined the waiting phase as the time during 
which the patient remains in the room without receiving any 
medical care. However, to assess in greater detail aspects 
of efficiency, it could be important to consider the issue of 
the catchment area for each DH, in terms of distribution of 
patients and distance to hospital.
Due to the lack of studies in Spain, it is difficult to 
compare the results obtained in our work. However, a con-
sideration of two calculation models enables us to evaluate 
the possible differences in the final results. The difference in 
the average total cost per treatment depends on the method 
used for imputing the staff costs. When we consider these 
costs solely as variable costs (imputed in accordance with 
the time spent on individualized direct care), we observe that 
the unit cost of the therapy is considerably smaller than the 
cost obtained by considering the whole of the salary bill for 
the medical staff employed by the DH. This estimate does 
not show the minimum to which the cost per infusion could 
be reduced in the DH by optimizing its efficiency, but it does 
show the component of this optimized cost which would 
be directly related to the individual and direct care of each 
patient. In this work, we observed large variations between 
hospitals in terms of staff employed and time spent on care; 
the difference between the shortest and the longest time taken 
by hospitals to administer an IV being 113 minutes, as an 
average for the four treatments analyzed. Focusing on the 
areas for potential improvement, we observed differences of 
up to 53 minutes in the waiting times at different DHs. The 
design of this study does not allow us to analyze the reasons 
for these differences in detail, so it would be useful to carry 
out future research to analyze the relationship between the 
funding of the hospitals and the waiting times, saturation 
ratios, and so on. In fact, it will be very interesting to develop 
future research using number of chairs available in each DH 
contrasted with physical space, in order to compare “packing” 
density of the hospitals.
This work does confirm that all these variables have an 
influence on the unit cost of administering medicines, and 
this invites us to believe that the optimization of resources 
would help to reduce costs and thus achieve greater effi-
ciency (Figure 5).
It is clear that the vast majority of the works published in 
our country use costs of administering biological therapies 
to patients with RA, which are taken from medical tariffs 
published by the autonomous communities that are themselves 
taken from the e-Salud database. This study was a pioneering 
study in Spain because it made an estimate of the cost of the 
Table 7 number of patients treated during the measurement period by Dh and disease group
Day  
Hospital
Total number of patients  
treated in DH during the  
measurement period
Total number of Rheumatology  
patients during the  
measurement period




Dh1 64 19 11 17.2%
Dh2 322 30 26 8.1%
Dh3 520 81 28 5.4%
Dh4 160 56 24 15%
Dh5 286 26 18 6.3%
Dh6 216 16 15 7%
Dh7 135 81 27 20%
Dh8 583 126 56 9.6%
Dh9 65 45 21 32.3%
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an estimate of the cost of administering intravenous biological agents
Figure 5 Ranking of hospitals, calculated in parts per unit, including the average, by total cost of treatment.
Abbreviations: Dh, day hospital; CiM, complete imputation method; PiM, partial imputation method; TRT, treatment.
biological agents applied to patients with RA, starting from 
primary data. So, in view of the results obtained in this work, 
it may be inferred that the data found in secondary sources 
are an estimate, on the high side, of the cost of administering 
biological agents in RA and, therefore, do not reflect the true 
cost of these treatments with any exactitude.
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